Effect of Glibenclamide as a KATP Channel Blockade in Treatment of Parkinson

Background: parkinson disease is the most common neurodegerative disease in the worldafter alzheimer disease. the most important cause of parkinson's is damage todopaminergic cells in the midbrain area. glibenclamide is a second-generation sulfonylurea;it has an inhibitory effect on surface and mitochondrial katp channels. many reports indicatethat glibenclamide can have neuroprotective effects in many neurodegenerative disorders.methods: in the present study, we investigated the effect of glibenclamide pretreatment onbehavioral symptom in 6-hydroxydopamine-induced animal model. rats were divided into 4groups (n=8 per group). group (i): control without intervention group (ii): vehicle, group (iii):received as pretreatment glibenclamide (3 mg/kg) i.p from begining of surgery until 4 weeksevery day. group (iv): received as pretreatment glibenclamide (8 mg/kg). in all group excepthealthy group received 6-ohda by stereotaxic surgery. development and severity ofparkinson disease were evaluated by apomorphine-induced rotational and rotarodbehavioral tests.results: our result showed that in two behavioral tests, pretreatment with glibenclamidecould attenuate severity of parkinson disease in treatment groups. there was no significantdifference between treatment groups with different doses of glibenclamide.conclusion: our data showed pretreatment with katp channel blockers reduces theseverity of parkinson's symptoms caused by the ohda-6 model in rats in behavioral studies.